CompanyGraph
What stands out
- Returns appear driven by leverage
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $808.21M, above the global median of $558.46M
- FinancialsAltman Z-Score 1.22: grey zone
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Returns appear driven by leverage
Financials view
Market Capitalization
698.41MUSDvs all stocks (USD)
Trailing P/E
17.74xRevenue (TTM)
808.21MUSDvs all stocks (USD)
Profit Margin
5.93%Beta
0.7190xvs all stocks
52-Week Change
-34.83%vs all stocks
Market Capitalization
698.41MUSDvs all stocks (USD)
Enterprise Value
1.82BUSDvs all stocks (USD)
Trailing P/E
17.74xForward P/E
3.37xPEG Ratio
-0.0803xPrice to Sales (TTM)
0.8641xPrice to Book (MRQ)
2.35xEnterprise to Revenue
2.25xEnterprise to EBITDA
4.50xGross Margin
55.18%Profit Margin
5.93%Operating Margin
5.65%Return on Assets (TTM)
5.75%Return on Equity (TTM)
17.61%Revenue (TTM)
808.21MUSDvs all stocks (USD)
Revenue per Share (TTM)
25.30USDUpdated Sep 27, 2026Quarterly Revenue Growth
6.30%Gross Profit (TTM)
722.93MUSDvs all stocks (USD)
EBITDA (TTM)
403.68MUSDvs all stocks (USD)
Net Income (TTM)
47.91MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
6.32%Operating Cash Flow (TTM)
329.92MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
324.04MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
780.57MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
317.31MUSDFY2025 · Dec 31, 2025Gross Profit
463.26MUSDFY2025 · Dec 31, 2025Operating Income
178.45MUSDvs all stocks (USD)
Pre-tax Income
92.62MUSDFY2025 · Dec 31, 2025Income Tax Expense
29.75MUSDFY2025 · Dec 31, 2025Net Income
62.87MUSDFY2025 · Dec 31, 2025EBIT
174.93MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
415.82MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
284.80MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.29MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
82.31MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.98USDFY2025 · Dec 31, 2025EPS (Diluted)
1.73USDFY2025 · Dec 31, 2025Basic Shares Outstanding
31.71MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
31.71MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
62.87MUSDFY2025 · Dec 31, 2025Operating Cash Flow
329.01MUSDFY2025 · Dec 31, 2025Free Cash Flow
327.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
252.16MUSDFY2025 · Dec 31, 2025Income Tax Paid
60.04MUSDFY2025 · Dec 31, 2025Interest Paid
68.76MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
62.87MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
226.07MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-25.66MUSDFY2025 · Dec 31, 2025Stock-based Compensation
41.91MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.45MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
17.20MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.55MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.74MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-126.97MUSDFY2025 · Dec 31, 2025Sale of Investments
65.18MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-63.53MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
565.17MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-635.56MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-25.10MUSDFY2025 · Dec 31, 2025Other Financing Charges
-20.40MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-115.89MUSDFY2025 · Dec 31, 2025Shares Outstanding
32.50MSharesUpdated Sep 27, 2026Float Shares
30.35MSharesUpdated Sep 27, 2026Shares Short
5.68MSharesUpdated Sep 27, 2026Short Ratio
6.65daysvs all stocks
Short % of Shares Outstanding
20.82%vs all stocks
% Held by Insiders
1.15%vs all stocks
% Held by Institutions
131.13%vs all stocks
Total Cash (MRQ)
129.47MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.98USDUpdated Sep 27, 2026Total Debt (MRQ)
1.22BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
3.90xCurrent Ratio (MRQ)
1.03xBook Value per Share (MRQ)
9.60USDUpdated Sep 27, 2026Total Assets
1.66BUSDvs all stocks (USD)
Total Current Assets
691.41MUSDFY2025 · Dec 31, 2025Total Liabilities
1.36BUSDFY2025 · Dec 31, 2025Total Non-current Assets
965.42MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
915.13MUSDFY2025 · Dec 31, 2025Total Current Liabilities
440.03MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
231.25MUSDFY2025 · Dec 31, 2025Other Short-term Investments
155.43MUSDFY2025 · Dec 31, 2025Accounts Receivable
211.33MUSDFY2025 · Dec 31, 2025Inventory
40.91MUSDFY2025 · Dec 31, 2025Accounts Payable
10.66MUSDFY2025 · Dec 31, 2025Short-term Debt
30.41MUSDFY2025 · Dec 31, 2025Deferred Revenue
667.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.44MUSDFY2025 · Dec 31, 2025Long-term Debt
784.46MUSDFY2025 · Dec 31, 2025Common Stock (Book)
41.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-101.13MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
301.68MUSDvs all stocks (USD)
Treasury Stock
222.51MUSDFY2025 · Dec 31, 202552-Week Low
21.65USDUpdated Sep 27, 202652-Week High
50.79USDUpdated Sep 27, 202652-Week Change
-34.83%vs all stocks
Beta
0.7190xvs all stocks
50-Day MA
28.37USDUpdated Sep 27, 2026200-Day MA
36.53USDUpdated Sep 27, 2026Avg 10-Day Volume
940.09KSharesUpdated Sep 27, 2026Avg 30-Day Volume
874.25KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
1.27USDUpdated Sep 27, 2026Other Income / Expense
-14.81MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Is this company growing?
Diagnostic
Total Revenue Growth With Buyback Amplification And Heavy SGA
Revenue is growing and buybacks shrink the share count, so per-share growth runs faster.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Where is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Returns appear driven by leverageSignificant
Return on Equity: 0.18Debt-to-Equity: 3.90
High gross margins eroded by operating costsNotable
Gross Margin: 0.55Profit Margin: 0.06
Financial Health
Altman Z-Score 1.22: grey zoneSignificant
Altman Z-Score: 1.22
High earnings qualityNotable
Earnings Quality Score: 3.63
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $808.21M, above the global median of $558.46MNotable
Revenue (USD): 808,208,000Global Median: 558,459,881.051
Levered free cash flow is $324.04M, above the global median of $18.92MNotable
Levered free cash flow (USD): 324,038,496Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gen Ilac ve Saglik Urunleri A.S.
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Shift4 Payments Inc.
5 interpretationsDrawdown With FCF And Cash BackingOperating Income Growing With Multi-Year Revenue GrowthClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And Book ValueWithin or Near the Altman Distress Zone
Planet Fitness Inc.
4 interpretationsDrawdown With FCF And Cash BackingOperating Income Growing With Multi-Year Revenue GrowthClose Below 40W SMA With ProfitabilityWithin or Near the Altman Distress Zone
Afya Ltd.
4 interpretationsDrawdown With FCF And Cash BackingOperating Income Growing With Multi-Year Revenue GrowthClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And Book Value